{"protocolSection":{"identificationModule":{"nctId":"NCT03979781","orgStudyIdInfo":{"id":"1158092"},"organization":{"fullName":"State University of New York - Upstate Medical University","class":"OTHER"},"briefTitle":"Personalized Antiplatelet Secondary Stroke PRevenTion","officialTitle":"Personalized Antiplatelet Secondary Stroke PRevenTion (PASSPoRT). A Randomized, Phase II, Open Label, Trial in High Risk Transient Ischemic Attack (TIA) and Ischemic Stroke Survivors Age 18 Years and Older","acronym":"PASSPoRT"},"statusModule":{"statusVerifiedDate":"2023-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-06-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-05-09","type":"ACTUAL"},"completionDateStruct":{"date":"2023-05-09","type":"ACTUAL"},"studyFirstSubmitDate":"2019-03-18","studyFirstSubmitQcDate":"2019-06-06","studyFirstPostDateStruct":{"date":"2019-06-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-12-14","lastUpdatePostDateStruct":{"date":"2023-12-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"State University of New York - Upstate Medical University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This is a descriptive study designed to evaluate the safety and feasibility of a precision medicine approach to antiplatelet selection for secondary stroke prevention.","detailedDescription":"Subjects meeting inclusion/exclusion criteria will be randomly assigned to: (1) the treatment group where antiplatelet medications will be selected using platelet function phenotype and/or key pharmacogene genotypes (2) the control group where participants will receive standard care for antiplatelet therapy (without knowledge of phenotype or genotype)."},"conditionsModule":{"conditions":["Ischemic Stroke","TIA"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":90,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment Group","type":"EXPERIMENTAL","description":"Intervention group","interventionNames":["Drug: tailored antiplatelet selection"]},{"label":"Control Group","type":"ACTIVE_COMPARATOR","description":"Standard of Care group","interventionNames":["Drug: standard of care"]}],"interventions":[{"type":"DRUG","name":"tailored antiplatelet selection","description":"antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes","armGroupLabels":["Treatment Group"]},{"type":"DRUG","name":"standard of care","description":"antiplatelet selection using standard of care","armGroupLabels":["Control Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Feasibility - Recruitment and Platelet Reactivity","description":"ability to recruit participants and achieve platelet reactivity target using platelet function assays","timeFrame":"90 days"},{"measure":"Safety - Bleeding Complications","description":"bleeding questionnaire","timeFrame":"90 days"},{"measure":"Safety - Bleeding Complications","description":"bleeding questionnaire","timeFrame":"1 year"}],"secondaryOutcomes":[{"measure":"Patient-centered Outcomes - Satisfaction","description":"consumer assessment of healthcare providers and systems","timeFrame":"90 days"},{"measure":"Patient-centered Outcomes - Satisfaction","description":"consumer assessment of healthcare providers and systems","timeFrame":"1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provide signed and dated informed consent form.\n* Willing to comply with all study procedures and be available for the duration of the study.\n* Meet criteria for a mild or moderate ischemic stroke or high-risk TIA\n* Ability to randomize within 30 hours of stroke symptom onset/last seen normal time\n\nExclusion Criteria:\n\n* Evidence of new or prior non-traumatic intracerebral hemorrhage, subarachnoid hemorrhage, or subdural hemorrhage on initial head CT\n* Evidence of a central nervous system tumor, abscess, intracranial aneurysm or vascular/structural malformation, or any neuro-inflammatory, neuro-infectious, or neurodegenerative disorder on neuroimaging or exam that could confound a participant's functional outcome\n* Isolated or pure sensory symptoms (e.g., numbness), visual changes, or \"dizziness\"/vertigo without evidence of acute ischemic stroke on baseline head CT or MRI.\n* Qualifying ischemic event is believed to be iatrogenic or procedure related\n* Required to take a specific antiplatelet medication for an indication other than ischemic stroke during the study period that would prevent the investigator from following the study algorithm\n* Etiology of qualifying ischemic event is known to be cardioembolic\n* High likelihood that anticoagulation will be needed during the study period.\n* High likelihood that carotid endarterectomy or carotid stenting will occur during the period of the study.\n* Pre-stroke modified Rankin scale (mRS) score ≥ 3\n* Evidence of frailty\n* Contraindication to aspirin, clopidogrel, Aggrenox®, or ticagrelor\n* Known allergy or hypersensitivity that would prevent the investigator from following the study algorithm\n* Any history of moderate to severe drug-induced adverse events\n* Renal insufficiency or history of kidney transplant\n* Hepatic impairment, international normalized ratio (INR) \\> 1.5, physical manifestations of liver disease, or history of liver transplant\n* Class II, III, or IV New York Heart Association (NYHA) functional heart failure\n* Any history of bradycardia without pacemaker placement\n* Active obstructive lung disease\n* Any active hematologic disorder\n* Active bleeding diathesis\n* Any systemic hemorrhage or GI bleed in the 3 months prior to the qualifying stroke\n* Active peptic ulcer disease\n* Women who self-report that they are pregnant or breastfeeding\n* Active alcohol or substance abuse or dependence\n* Inability or failure to provide informed consent.\n* Inability of the patient to adhere to study procedures and/or follow-up, in the opinion of the investigative team\n* Inability to swallow oral medications\n* Not willing or able to discontinue prohibited concomitant medications\n* Ongoing participation in another non-observational clinical study\n* Life expectancy \\< 1 year, in the opinion of the investigative team","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Karen C Albright, PhD, DO","affiliation":"State University of New York - Upstate Medical University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"SUNY Upstate Medical University","city":"Syracuse","state":"New York","zip":"13202","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5485","name":"Ischemic Attack, Transient","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}